Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Cyclerion Therapeutics announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET. Investors can request individual meetings through Jefferies. The presentation will be accessible via the Investors & Media section of the Cyclerion website, and an archived replay will be available for 90 days post-event.

Cyclerion is focused on developing treatments to restore cognitive function, with its lead compound CY6463 currently in clinical trials for Alzheimer's Disease and other cognitive impairments.

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available for one-on-one meetings and investors may request a meeting through Jefferies.

The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the event will be available on the site for approximately 90 days following the presentation.

About Cyclerion Therapeutics 

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’ is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

FAQ

What is the date and time of Cyclerion's presentation at the Jefferies Virtual Healthcare Conference?

Cyclerion Therapeutics will present on June 1, 2021, at 4:00 p.m. ET.

How can I access Cyclerion's presentation at the Jefferies Virtual Healthcare Conference?

The presentation can be accessed via the Investors & Media section of Cyclerion's website.

What is Cyclerion Therapeutics' lead compound and its purpose?

The lead compound is CY6463, which aims to improve cognitive function and is currently in clinical development for Alzheimer's Disease, MELAS, and CIAS.

Will there be a replay of the Cyclerion presentation available?

Yes, an archived replay of the presentation will be available for approximately 90 days after the event.

What types of diseases is CY6463 targeting?

CY6463 is being developed for Alzheimer’s Disease with vascular pathology, MELAS, and cognitive impairment associated with schizophrenia.